DE60224280D1 - Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis - Google Patents

Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis

Info

Publication number
DE60224280D1
DE60224280D1 DE60224280T DE60224280T DE60224280D1 DE 60224280 D1 DE60224280 D1 DE 60224280D1 DE 60224280 T DE60224280 T DE 60224280T DE 60224280 T DE60224280 T DE 60224280T DE 60224280 D1 DE60224280 D1 DE 60224280D1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
eustasis
oxytocin
effectiveness
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60224280T
Other languages
English (en)
Inventor
Kerstin Uvnaes-Moberg
Thomas Lundeberg
Maria Petersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60224280D1 publication Critical patent/DE60224280D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60224280T 2001-06-19 2002-06-19 Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis Expired - Lifetime DE60224280D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0102184A SE0102184D0 (sv) 2001-06-19 2001-06-19 New subject-matter
PCT/SE2002/001207 WO2002102832A1 (en) 2001-06-19 2002-06-19 Use of fragments of oxytocin for the preparation of a pharmaceutical composition in order to create eustasis

Publications (1)

Publication Number Publication Date
DE60224280D1 true DE60224280D1 (de) 2008-02-07

Family

ID=20284539

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60224280T Expired - Lifetime DE60224280D1 (de) 2001-06-19 2002-06-19 Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis

Country Status (6)

Country Link
US (1) US7714105B2 (de)
EP (1) EP1409518B1 (de)
AT (1) ATE382054T1 (de)
DE (1) DE60224280D1 (de)
SE (1) SE0102184D0 (de)
WO (1) WO2002102832A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1741719B1 (de) 2004-03-31 2015-02-25 Patent Technology Development Inc. Epithelzellenwachstumspromotor
FR2954167A1 (fr) 2009-09-04 2011-06-24 Centre Nat Rech Scient Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique
SE536091C2 (sv) 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
AU2016205225A1 (en) 2015-01-07 2017-08-17 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
JP6527996B2 (ja) * 2017-09-12 2019-06-12 株式会社 金冠堂 Ｆｇｆ活性に影響を与えるジペプチド

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) * 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
EP0146113A3 (de) 1983-12-15 1987-08-19 Dieter Aderhold Wirkstoff und therapeutisches Mittel zur Behandlung von Fehlfunktionen des Diencephalon, von Nervenerkrankungen und Erkrankungen der Haut
US5767083A (en) * 1994-05-04 1998-06-16 Innapharma, Inc. Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent
SE9803271D0 (sv) 1998-09-25 1998-09-25 Kerstin Uvnaes Moberg A drug for well-being

Also Published As

Publication number Publication date
WO2002102832A1 (en) 2002-12-27
SE0102184D0 (sv) 2001-06-19
US20040259805A1 (en) 2004-12-23
EP1409518A1 (de) 2004-04-21
ATE382054T1 (de) 2008-01-15
EP1409518B1 (de) 2007-12-26
US7714105B2 (en) 2010-05-11

Similar Documents

Publication Publication Date Title
PT1049767E (pt) Coelho transgenico que expressa uma lipoproteina (a) humana funcional
ATE446313T1 (de) Muteine von tränen-lipocalin
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
BR0112540A (pt) Peptìdios como inibidores da ns-3-serina protease do vìrus da hepatite c
CY1106774T1 (el) Συνθεσεις φαρμακευτικων μεσων με βαση αλατα του τιοτροπιου και αλατα της σαλμετερολης
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
DE60222644D1 (de) Prozess zur herstellung von transparenten formteilen
BR9910573A (pt) Compostos antipicornavirais, preparação e uso dos mesmos
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DE60129518D1 (de) Verwendung von einem Vasopressin-Antagonisten wie Conivaptan zur Herstellung eines Medikaments für die Behandlung der pulmonalen Hypertension
PL374080A1 (en) Processes for the preparation of fibrinogen
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
DE50113345D1 (de) Arginin-mimetika als faktor xa-inhibitoren
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
WO2004110349A3 (en) Sars t cell epitopes and methods for identifying same
DE60224280D1 (de) Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
DK1476467T3 (da) IgG3-immunglobulin som beskyttelsesmarkör mod virusinfektionssygdomme og anvendelser deraf
DE60239670D1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
DE60033207D1 (de) Werkzeug zur herstellung von nockenwellen durch einwalzen
DE50304242D1 (de) Verfahren zur herstellung von acylphosphinoxiden
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen

Legal Events

Date Code Title Description
8332 No legal effect for de